相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study
Wan Ni Chia et al.
LANCET MICROBE (2021)
Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19
Lauren B. Rodda et al.
CELL (2021)
Adaptive immunity to SARS-CoV-2 and COVID-19
Alessandro Sette et al.
CELL (2021)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Merryn Voysey et al.
LANCET (2021)
Correlates of protection against SARS-CoV-2 in rhesus macaques
Katherine McMahan et al.
NATURE (2021)
Evolution of antibody immunity to SARS-CoV-2
Christian Gaebler et al.
NATURE (2021)
Looking beyond COVID-19 vaccine phase 3 trials
Jerome H. Kim et al.
NATURE MEDICINE (2021)
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
Alicia T. Widge et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine
J. Sadoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
S. F. Lumley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
Jennifer M. Dan et al.
SCIENCE (2021)
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
Daming Zhou et al.
CELL (2021)
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Denis Y. Logunov et al.
LANCET (2021)
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Yanjun Zhang et al.
LANCET INFECTIOUS DISEASES (2021)
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial
Raches Ella et al.
LANCET INFECTIOUS DISEASES (2021)
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Pengfei Wang et al.
NATURE (2021)
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Zijun Wang et al.
NATURE (2021)
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Rita E. Chen et al.
NATURE MEDICINE (2021)
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine
Kai Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Neutralizing Activity of BNT162b2-Elicited Serum
Yang Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19
Adam K. Wheatley et al.
NATURE COMMUNICATIONS (2021)
Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant
Elisabeth Mahase
BMJ-BRITISH MEDICAL JOURNAL (2021)
Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection
Deborah Cromer et al.
NATURE REVIEWS IMMUNOLOGY (2021)
Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes
Edwards Pradenas et al.
MED (2021)
Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Katharine H. D. Crawford et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
Influenza A Reinfection in Sequential Human Challenge: Implications for Protective Immunity and Universal Vaccine Development
Matthew J. Memoli et al.
CLINICAL INFECTIOUS DISEASES (2020)
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Pedro M. Folegatti et al.
LANCET (2020)
Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity
Carolyn Rydyznski Moderbacher et al.
CELL (2020)
Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19
Jennifer A. Juno et al.
NATURE MEDICINE (2020)
Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19
F. Javier Ibarrondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
An mRNA Vaccine against SARS-CoV-2-Preliminary Report
L. A. Jackson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
Thomas F. Rogers et al.
SCIENCE (2020)
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
Edward E. Walsh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Cheryl Keech et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models
David S. Khoury et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Heterogeneity and longevity of antibody memory to viruses and vaccines
Alice Antia et al.
PLOS BIOLOGY (2018)
Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model
Matthew J. Memoli et al.
MBIO (2016)
Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection
Arnold S. Monto et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Confidence intervals for ratios of proportions: implications for selection ratios
Ken Aho et al.
METHODS IN ECOLOGY AND EVOLUTION (2015)
Who Invented the Delta Method?
Jay M. Ver Hoef
AMERICAN STATISTICIAN (2012)
Comparison of neutralizing and hemagglutination-inhibiting antibody responses for evaluating the seasonal influenza vaccine
Li-Wei Cheng et al.
JOURNAL OF VIROLOGICAL METHODS (2012)
Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated Influenza Vaccines in Children
Steven Black et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2011)
Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model
Laurent Coudeville et al.
BMC MEDICAL RESEARCH METHODOLOGY (2010)
Fast Implementation for Normal Mixed Effects Models With Censored Response
Florin Vaida et al.
JOURNAL OF COMPUTATIONAL AND GRAPHICAL STATISTICS (2009)
Duration of humoral immunity to common viral and vaccine antigens
Ian J. Amanna et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A framework for assessing immunological correlates of protection in vaccine trials
Li Qin et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
A model for immunological correlates of protection
AJ Dunning
STATISTICS IN MEDICINE (2006)